TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06363773

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiotherapy
Description: Patients will perform stereotactic radiotherapy with 3 sessions (8 Gy) during 20 minutes each and with 72 hours in-between.~Patients enrolled in the study would not have received this stereotactic radiotherapy outside the study, that is why this procedure is additional (compared to Standard of care) and considered as burdensome (as this is radiation). Before performing the stereotactic radiotherapy, patients will do a radiotherapy CT scanner (no injected) in order to prepare precisely the radiotherapy (treatment plan).
Study: NCT06558383

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: augmented posterior oblique sling activation
Description: activation of posterior oblique sling for 18 sessions, three sessions per week for six weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: selected physical therapy program
Description: selected physical therapy program for 18 sessions, three sessions per week for six weeks in form hot packs, soft tissue techniques, mobilization and manipulation of lumbar spine, and neurodynamics and stabilization exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: selected physical therapy program
Description: selected physical therapy program for 18 sessions, three sessions per week for six weeks in form hot packs, soft tissue techniques, mobilization and manipulation of lumbar spine, and neurodynamics and stabilization exercises
Study: NCT05498844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Nutrition Therapy (counselling)
Description: Participants will receive nutrition counseling to enhance adherence to the principles of the Mediterranean diet and support the achievement of adequate levels of lipid control, blood pressure and weight.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical Nutrition Therapy (counselling)
Description: Participants will receive nutrition counseling to enhance adherence to the principles of the Mediterranean diet and support the achievement of adequate levels of lipid control, blood pressure and weight.
Study: NCT05010252

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cycled light Experimental
Description: The preliminary plan of this study is to carry out empirical evidence and expert advice to confirm precise lighting and develop care intervention strategies for preterm infants based on evidence. It is planned to be in the Neonatal Intermediate Care Nursery, National Taiwan University Children's Hospital, and the subjects are premature babies born 32 weeks old. Divided into two groups of light intervention group and control group, longitudinal tracking intervention effect and six-weeks and three-months delay effect.
Study: NCT04797780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamibarotene
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azacitidine
Description: Administered as specified in the treatment arm
Study: NCT05543291

Intervention type: BEHAVIORAL
Intervention: renal function
Description: levels of eGFR

Intervention type: BEHAVIORAL
Intervention: renal function
Description: levels of eGFR

Intervention type: BEHAVIORAL
Intervention: renal function
Description: levels of eGFR

Intervention type: BEHAVIORAL
Intervention: renal function
Description: levels of eGFR
Study: NCT06119984

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community mobilization
Description: The intervention focused on creating awareness, challenging social norms, and promoting actions against violence. To achieve these, the following activities were undertaken: introductory meetings, selection and training of model couples, structured workshops and small group meetings.
Study: NCT05307770

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immediate Release Melatonin
Description: 5 mg orally every night at 9 pm for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immediate Release Melatonin
Description: 5 mg orally every night at 9 pm for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extended Release Melatonin
Description: 5 mg orally every night at 9 pm for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extended Release Melatonin
Description: 5 mg orally every night at 9 pm for 4 weeks
Study: NCT06223412

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: video-based climate change program
Description: The participants in this group received a series of short videos, ranging between 30- 45 minutes/ each video revolved around five core themes including The road start to green planet, The ripple effect climate change on Health, Climate Change Literacy, Strengthen resilience to overcome climate related- psychological impacts, and Sustaining phase: closing session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video-based climate change program
Description: The participants in this group received a series of short videos, ranging between 30- 45 minutes/ each video revolved around five core themes including The road start to green planet, The ripple effect climate change on Health, Climate Change Literacy, Strengthen resilience to overcome climate related- psychological impacts, and Sustaining phase: closing session.
Study: NCT06528483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan + Zimberelimab
Description: Sacituzumab Govitecan 7.5 mg/kg IV for 3 cycles Zimberelimab 360 mg IV for 16 cycles~Patients will be treated with Sacituzumab Govitecan 1,8q21 plus + Zimberelimab q21 for 3 cycles then radiological imaging and TURB will be repeated and patients with Stability of disease or down staging will continue Zimberelimab until disease progression, or unacceptable toxicities or completion of treatment (16 cycles). Patients with progressive disease after 3 cycles of study intervention will be treated as per clinical practice.
Study: NCT05017233

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectral CT
Description: Using Spectral CT to scan Breast
Study: NCT05794438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Static Approach Bias Modification
Description: In the static approach bias modification, users were instructed to swipe upward when they see portrait format images and swipe downward when they see landscape format images. A shrinking animation comes after swiping upward to simulate the visual effect of moving away (approach), and a growing animation comes after swiping downward to simulate the visual effect of moving towards (avoidance). Two types of images, namely drug-related and non-drug-related, were used in the training. The drug-related images were related to methamphetamine (methamphetamine crystals, powders, and paraphernalia), and the non-drug-related images were related to healthy lifestyles (wealth, sports, gourmet, family activities, etc).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Approach Bias Modification
Description: In the adaptive approach bias modification, users were instructed to swipe upward when they see portrait format images and swipe downward when they see landscape format images. A shrinking animation comes after swiping upward to simulate the visual effect of moving away (approach), and a growing animation comes after swiping downward to simulate the visual effect of moving towards (avoidance). Two types of images, namely drug-related and non-drug-related, were used in the training. The drug-related images were related to methamphetamine (methamphetamine crystals, powders, and paraphernalia), and the non-drug-related images were related to healthy lifestyles (wealth, sports, gourmet, family activities, etc). An algorithm continuously monitors the performance of the user and adjusts the ratio of congruent and incongruent trials accordingly to attain a desired difficulty curve.
Study: NCT06187922

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 75mg
Description: Group pregabalin will receive cap pregabalin 75mg as premedication and will continue as B.D dose for 72 Hrs.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: adductor canal block
Description: Both group will receive ultrasound guided Adductor canal block with bupivacaine 0.2% 20-30ml and dexmedetomidine 1mcg/Kg

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adductor canal block
Description: Both group will receive ultrasound guided Adductor canal block with bupivacaine 0.2% 20-30ml and dexmedetomidine 1mcg/Kg
Study: NCT06343051

Intervention type: DEVICE
Intervention: USCOM
Description: Device that measures how much blood is being pumped in and out of the heart.
Study: NCT05955352

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perineal warm compression Technique
Description: There will be two groups. Interventional group will receive perineal warm compression and control group will receive standard care to asses the pain intensity and perineal tear
Study: NCT05885360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istradefylline Pill
Description: Istradefylline targets adenosine A2A receptors in the basal ganglia, by inhibiting the indirect pathway It is an adjunctive treatment to carbidopa-levodopa indicated to improve on time and decrease off time.
Study: NCT06216522

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Sesame Oil
Description: 5 drops/0.25mls of sesame oil applied to the IV cannula site at 12 hourly intervals for 72 hours

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Liquid paraffin oil
Description: 5 drops/0.25mls of liquid paraffin oil applied to the IV cannula site at 12 hourly intervals for 72 hours
Study: NCT05618548

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: COVID-19 vaccine available at the moment of vaccination: either the Comirnaty vaccine (mRNA, Pfizer BioNtech), the Moderna vaccine (mRNA, Moderna), the Vaxzevria vaccine (Viral Vector, Astra Zeneca).

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: COVID-19 vaccine available at the moment of vaccination: either the Comirnaty vaccine (mRNA, Pfizer BioNtech), the Moderna vaccine (mRNA, Moderna), the Vaxzevria vaccine (Viral Vector, Astra Zeneca).

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: COVID-19 vaccine available at the moment of vaccination: either the Comirnaty vaccine (mRNA, Pfizer BioNtech), the Moderna vaccine (mRNA, Moderna), the Vaxzevria vaccine (Viral Vector, Astra Zeneca).

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: COVID-19 vaccine available at the moment of vaccination: either the Comirnaty vaccine (mRNA, Pfizer BioNtech), the Moderna vaccine (mRNA, Moderna), the Vaxzevria vaccine (Viral Vector, Astra Zeneca).
Study: NCT06352372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: noninvasively delivered near infra-red (NIR) light - transcranial Photobiomodulation (tPBM)
Description: The proposed intervention will be noninvasively delivered near infra-red (NIR) light - transcranial Photobiomodulation (tPBM) - to the brains of autistic children. The NIR light is delivered to specific brain areas by Cognilum, a wearable device developed by Jelikalite. The expected outcome is improved focus, improved eye contact, improved speech, improved behavior, and gains in functional skills.
Study: NCT05453825

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: navicixizumab+paclitaxel
Description: navicixizumab 3 mg/kg Q2W; paclitaxel 80 mg/m2 weekly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: navicixizumab+irinotecan
Description: navicixizumab 3 mg/kg Q2W; irinotecan 180 mg/m2 Q2W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: navicixizumab monotherapy
Description: navicixizumab 3 mg/kg Q2W
Study: NCT06347094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Dietary Plan
Description: Prescription of dietary plans increasing the intake of (poly)phenols through consumption of foods rich in these compounds, in the context of a balanced, personalised diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Dietary Plan
Description: Prescription of dietary plans increasing the intake of (poly)phenols through consumption of foods rich in these compounds, in the context of a balanced, personalised diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral (Poly)phenol Challenge Test (OPCT)
Description: Nutritional challenge with standardized (poly)phenol-rich tablets

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral (Poly)phenol Challenge Test (OPCT)
Description: Nutritional challenge with standardized (poly)phenol-rich tablets

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral (Poly)phenol Challenge Test (OPCT)
Description: Nutritional challenge with standardized (poly)phenol-rich tablets

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral (Poly)phenol Challenge Test (OPCT)
Description: Nutritional challenge with standardized (poly)phenol-rich tablets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General Dietary Advice
Description: Prescription of balanced dietary plans

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General Dietary Advice
Description: Prescription of balanced dietary plans
Study: NCT01175525

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CROMOLYN
Description: Cromolyn 200mg (dissolved in water) given 4 times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: sugar pill Dissolved in water taken 4 times daily 30 minutes prior to meals
Study: NCT06509126

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panitumumab
Description: Administered at the dosage of 6mg/kg as 60 minutes, or 90 minutes for doses over 1000 mg, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Administered at the dosage of 6mg/kg as 60 minutes, or 90 minutes for doses over 1000 mg, intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Administered at the dosage of 180 mg/m2 over 60 minutes intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Administered at the dosage of 180 mg/m2 over 60 minutes intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: Administered at the dosage of 400 mg/m2 (bolus intravenous infusion) followed by continuous intravenous infusion over 46 hours at the dosage of 2400 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Administered at the dosage of 400 mg/m2 (bolus intravenous infusion) followed by continuous intravenous infusion over 46 hours at the dosage of 2400 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-folinic acid
Description: Administered at the dosage of 200 mg/m2 over 120 minutes as intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-folinic acid
Description: Administered at the dosage of 200 mg/m2 over 120 minutes as intravenous infusion
Study: NCT05129319

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prabotulinumtoxinA
Description: Injection of glabellar rhytids

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prabotulinumtoxinA
Description: Injection of glabellar rhytids
Study: NCT05721131

Intervention type: DEVICE
Intervention: NC° Thermometer (Gen 3)
Description: The NC° Thermometer (Gen3) is used orally for the intermittent measurement and monitoring of human body temperature. The device can be used by adults and children over the age of 5 years old.
Study: NCT06540638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web based education program
Description: In a pre-operative assessment, 1-30 days prior to their scheduled surgery, patients will be asked to participate in our web-based educational program. The content of our e-module included: introduction to brain health, surgery, and delirium, causes and risk factors, modifiable risk factors, and delirium prevention. The program will be delivered on a research laptop/iPad at the clinic. The entire program, including pre- and post-education questionnaires and satisfaction survey should take about 20 minutes to complete.
Study: NCT05953688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESK-001
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESK-001
Description: Oral tablet
Study: NCT05932693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-liquid coolant (WS-3, 0.05%)
Description: Adult users of e-cigarette will be exposed to five e-liquid coolants WS-3: 0.05%.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-liquid coolant (WS-3, 0.1%)
Description: Adult users of e-cigarette will be exposed to five e-liquid coolants WS-3: 0.1%.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-liquid coolant (WS-3, 0.5%)
Description: Adult users of e-cigarette will be exposed to five e-liquid coolants WS-3: 0.5%.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-liquid coolant (WS-3, 1.0%)
Description: Adult users of e-cigarette will be exposed to five e-liquid coolants WS-3: 1.0%.
Study: NCT05164575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: progressive resistance exercise
Description: Progressive resistance exercise program and self-management strategies. Participants will be provided with Theraband to progress exercise intensity, a FitBit to monitor physical activity, an audio-journal to promote self-reflection, and educational materials provided as part of usual OA care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: progressive resistance exercise
Description: Progressive resistance exercise program and self-management strategies. Participants will be provided with Theraband to progress exercise intensity, a FitBit to monitor physical activity, an audio-journal to promote self-reflection, and educational materials provided as part of usual OA care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-management strategies
Description: Progressive resistance exercise program and self-management strategies. Participants will be provided with Theraband to progress exercise intensity, a FitBit to monitor physical activity, an audio-journal to promote self-reflection, and educational materials provided as part of usual OA care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-management strategies
Description: Progressive resistance exercise program and self-management strategies. Participants will be provided with Theraband to progress exercise intensity, a FitBit to monitor physical activity, an audio-journal to promote self-reflection, and educational materials provided as part of usual OA care.
Study: NCT06088940

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multistrain Probiotic
Description: The probiotic capsule contains Lactobacillus and Bifidobacterium strains, ingested orally once daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is composed of maltodextrin, that is an identically formulated and packaged inactive substance
Study: NCT06162650

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy
Description: Short-course radiotherapy, 5×5 Gy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: Oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, infusinal 5-fluorouracil 2400 mg/m2 every 2 weeks, for 9 cycles
Study: NCT06146491

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral tablet and transdermal patch
Description: oral combination of paracetamol -500mg and ibuprofen - 400mg will be given to group A and transdermal diclofenac patch - 200 mg will be given to group B.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral tablet and transdermal patch
Description: oral combination of paracetamol -500mg and ibuprofen - 400mg will be given to group A and transdermal diclofenac patch - 200 mg will be given to group B.
Study: NCT06511336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alkaline water (FLO water- Bottled drinking water- the Egyption Saudi Company for natural water- made in Egypt
Description: children will use Alkaline water as mouthwash daily for 3 weeks. each time they will use 10 ml of their mouthwash for 30 seconds

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alkaline water (FLO water- Bottled drinking water- the Egyption Saudi Company for natural water- made in Egypt
Description: children will use Alkaline water as mouthwash daily for 3 weeks. each time they will use 10 ml of their mouthwash for 30 seconds

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alkaline water (FLO water- Bottled drinking water- the Egyption Saudi Company for natural water- made in Egypt
Description: children will use Alkaline water as mouthwash daily for 3 weeks. each time they will use 10 ml of their mouthwash for 30 seconds
Study: NCT05843916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human alpha galactosidase A (agalsidase beta)
Description: All participants will receive 2 doses of Fabrazyme® with approximately 14 days between them. The dose will be 1 mg/kg of body mass every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human alpha-galactosidase A (agalsidase beta)
Description: All participants will receive AGA BETA BS for 54 weeks. The dose will be 1 mg/kg of body mass every 2 weeks
Study: NCT06048510

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pregnant women
Description: Gestational Diabetes Mellitus increases the risk of adverse pregnancy outcomes (such as macrosomia).~The lack of early clinical symptoms leads to screen pregnant women for GDM, and the strategies of screening are a matter of debate.~Interventions to control glucose levels in women with GDM have demonstrated efficacy in terms of macrosomia. However, macrosomia may start before the time of screening, suggesting that markers of glycation may have interest : skin autofluorescence, glycated albumin.